Team:NTU-Singapore

From 2009.igem.org

Revision as of 06:35, 16 October 2009 by Iandravid (Talk | contribs)


Hello iGEM.

Welcome to the official Nanyang Technological University project wiki for iGEM '09.

This site looks best in Gecko/Webkit based browsers.


About our project

Atherosclerosis is a growing healthcare concern, affecting millions of people worldwide every year. Conventional treatments only treat the symptoms, but do not prevent or cure the problem! The NTU iGEM ’09 team is proud to announce that we are working on a proposed alternative treatment for this disease.


Our system in its physiological conditions
Our system, pLaqUe Out!, ideally in a macrophage chassis, can be introduced into the bloodstream.


It will be activated by a symptom that is typical of plaque buildup.


Upon activation, our system will release a cholesterol degrading enzyme, a novel reporter protein and a vasodilator.



  1. The sense construct triggers the system in response to falling nitric oxide concentrations.
  2. The cholesterol degrading enzyme breaks down the plaque.
  3. The reporter protein, with its unique fluorescent property, allows the plaque site to be visualized in vivo.
  4. Finally, the vasodilator will simultaneously dilate the blood vessels for better flow, as well as switch off the extended activity of our system.

For now, E. coli is used as a model organism to test our system.


Accomplishments!

About the team

This marks the second year NTU-Singapore is taking part in this competition. The team consists of 8 undergraduates, guided by 7 instructors and 3 advisors. We are really looking forward to pitting our minds against top minds in universities worldwide, and eventually meeting everyone at the iGEM Jamboree. Good luck everyone!



Our top sponsors

We would like to sincerely thank our Gold sponsors, Genentech Singapore and Johnson & Johnson Singapore for their invaluable contribution to the team!


Genentech
Johnson & Johnson

Visitor's info

Locations of visitors to this page



NTU@iGEMcc 2009. Some rights reserved.